Clinical Trial Update: Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of BHV-3000 (rimegepant) orally disintegrating tablet for acute treatment of chronic rhinosinusitis with and wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinosinusitis
• Rhinosinusitis with Nasal Polyps

Drugs mentioned

• BHV-3000 (Rimegepant) Orally Disintegrating Tablet (rimegepant)

Snippet

Sponsor: Pfizer | Conditions: Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps | Phase 3 | Status: COMPLETED | Results posted: 2025-03-26